THERMOSTABLE PHYTASE VARIANTS
    5.
    发明公开
    THERMOSTABLE PHYTASE VARIANTS 审中-公开
    热稳定的植物酶变体

    公开(公告)号:EP2553091A1

    公开(公告)日:2013-02-06

    申请号:EP11709972.1

    申请日:2011-03-25

    申请人: Novozymes A/S

    摘要: The present invention relates to a phytase which has at least 70% identity to a phytase derived from E. coli and comprises at least one modification as compared to this phytase. These phytase variants have modified, preferably improved, properties, such as thermostability, temperature profile, pH profile, specific activity, performance in animal feed, reduced protease sensibility, and/or an modified glycosylation pattern. The invention also relates to DNA encoding these phytases, methods of their production, as well as the use thereof, e.g. in animal feed and animal feed additives.

    摘要翻译: 本发明涉及与来源于大肠杆菌的肌醇六磷酸酶具有至少70%同一性且与该肌醇六磷酸酶相比包含至少一种修饰的肌醇六磷酸酶。 这些肌醇六磷酸酶变体具有修饰的,优选改进的性质,例如热稳定性,温度曲线,pH曲线,比活性,动物饲料中的性能,降低的蛋白酶敏感性和/或修饰的糖基化模式。 本发明还涉及编码这些肌醇六磷酸酶的DNA,它们的生产方法及其用途,例如, 在动物饲料和动物饲料添加剂中。

    LIPASE VARIANTS FOR PHARMACEUTICAL USE
    7.
    发明公开
    LIPASE VARIANTS FOR PHARMACEUTICAL USE 审中-公开
    LIPASE-VARIANTEN ZUR PHARMAZEUTISCHEN VERWENDUNG

    公开(公告)号:EP2099907A2

    公开(公告)日:2009-09-16

    申请号:EP07869130.0

    申请日:2007-12-12

    IPC分类号: C12N9/20 A61K38/46 A61K38/54

    摘要: The pharmaceutical use of lipases related to the Thermomyces lanuginosus (Humicola lanuginosa) lipase comprising amino acids 1-269 of SEQ ID NO: 2, optionally in combination with a protease and/or an amylase. Examples of medical indications are: Treatment of digestive disorders, pancreatic exocrine insufficiency (PEI), pancreatitis, cystic fibrosis, diabetes type I, and/or diabetes type II. The lipases of the invention have, e.g., an improved digestion performance in vitro, an improved activity at a pH in the neutral range, an improved stability at low pH, an are stable against protease-degradation, and/or are stable in the presence of pepsin and bile salts. The invention also relates to methods of determining digestion performance in vitro of lipases, as well as to certain novel variants of the lipase of T. lanuginosus.

    摘要翻译: 与包含SEQ ID NO:2的氨基酸1-269,至少具有取代N33Q,T231R,N233R和D254S的Thermomyces lanuginosus(Humicola lanuginosa)脂肪酶相关的脂肪酶的药物用途任选与蛋白酶和/或淀粉酶组合 。 医学适应症的例子有:消化系统疾病,胰腺外分泌功能不全(PEI),胰腺炎,囊性纤维化,I型糖尿病和/或II型糖尿病的治疗。 本发明的脂肪酶具有例如体外改善的消化性能,在中性范围内的pH值改善的活性,在低pH下的改善的稳定性,对蛋白酶降解是稳定的,和/或在存在 胃蛋白酶和胆汁盐。 本发明还涉及确定脂肪酶的体外消化性能的方法以及T.lanuginosus的脂肪酶的某些新颖变体。

    LYSOZYMES
    10.
    发明公开
    LYSOZYMES 审中-公开
    溶菌酶

    公开(公告)号:EP2616483A1

    公开(公告)日:2013-07-24

    申请号:EP11757855.9

    申请日:2011-09-15

    申请人: Novozymes A/S

    IPC分类号: C07K14/465 C12N9/36

    摘要: The present invention is directed to lysozyme variants and nucleotide sequences encoding same. The lysozyme variants have antimicrobial and/or lysozyme activity and comprise an alteration of an amino acid sequence at one or more positions. The present invention is also directed to methods for producing and of using the Opisthocomus hoazin lysozyme and the lysozyme variants of the present invention as antimicrobial agents.

    摘要翻译: 本发明涉及溶菌酶变体和编码其的核苷酸序列。 溶菌酶变体具有抗微生物和/或溶菌酶活性,并且包括在一个或多个位置上氨基酸序列的改变。 本发明还涉及用于生产和使用本发明的黑荆芥属溶菌酶和溶菌酶变体作为抗微生物剂的方法。